Weisberg

Endonovo’s SofPulse® Secures Federal Supply Schedule Inclusion to Accelerate Expansion of VA Distribution

Retrieved on: 
Tuesday, August 22, 2023
SDVOSB, Partnership, PEMF, Knoxville Veterans Administration Hospital Historic District, FSS, Edema, OTCQB, Service-Disabled Veteran-Owned Small Business, Inflammation, Government, Military personnel, NAC, Pain, Healthcare Facilities Accreditation Program, Weisberg, Patient, United States Department of Veterans Affairs, Growth, DAFA, FDA, Therapy, Health, SAC, Department of Defence, Health insurance, Pharmaceutical industry, Federal

Los Angeles, CA, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) -- a US-based commercial medical device company -- today announced its inclusion on the Federal Supply Schedule (FSS) for SofPulse® Pulsed Electro Magnetic Field (PEMF) medical devices for distribution throughout the Federal healthcare supply channels.

Key Points: 
  • Los Angeles, CA, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) -- a US-based commercial medical device company -- today announced its inclusion on the Federal Supply Schedule (FSS) for SofPulse® Pulsed Electro Magnetic Field (PEMF) medical devices for distribution throughout the Federal healthcare supply channels.
  • SofPulse® is an FDA-Cleared medical device which is recognized for its exceptional efficacy for postoperative reduction of pain and edema (inflammation).
  • Endonovo has identified numerous governmental healthcare contracts for the expansion of distribution throughout the government healthcare sectors.
  • Weisberg concluded: “To streamline our government distribution expansion, we have established pre-negotiated prices, terms, deliverables, warranties and other details to aid in making the purchasing process more straightforward.

Endonovo’s Breaking Barriers in With Patented Medical Technologies: 2023 Bi-Annual Update

Retrieved on: 
Tuesday, August 8, 2023
Marketing, Stanford University, Electromagnetic hypersensitivity, Patient, Concussion, Stroke, Columbia University, NFL, Telehealth, Headache, Therapy, Defense, OTCQB, Research, TBI, Attention, Veteran, Athlete, Dementia, Growth, FDA, Post-concussion syndrome, Deficit spending, Multiple sclerosis, Compound annual growth rate, Dizziness, PCS, Partnership, PEMF, Traumatic brain injury, Veterans Health Administration, Quality of life, Inflammation, CNS, Disorder, Central nervous system, Management, Pharmaceutical industry, Weisberg

The strategic hiring of Weisberg to lead sales, marketing and brand initiatives is set to drive Endonovo's expansion and distribution efforts.

Key Points: 
  • The strategic hiring of Weisberg to lead sales, marketing and brand initiatives is set to drive Endonovo's expansion and distribution efforts.
  • The Company's innovative approach to pain relief and non-opioid alternatives has garnered widespread attention in expanding medical markets.
  • In the first quarter of 2023, we solidified a strategic partnership with Academy Medical, a leading distribution company, serving Veterans and Dept of Defense patients.
  • The agreement can help to play a pivotal role in delivering essential PEMF- therapies and medical products to government facilities.

Endonovo Announces Binding Letter of Intent to Sell SofPulse® Assets to Spin-Off Company

Retrieved on: 
Wednesday, March 29, 2023
Spin-off, PEMF, Marketing, Intellectual property, Edema, OTCQB, IP, LOI, Weisberg, Acquisition, Patient, U.S. Department of Defense Strategy for Operating in Cyberspace, Pain management, FMV, Therapy, Corporate spin-off, Pharmaceutical industry, Risk management, Ocean Tomo

As previously announced, Endonovo hired Ocean Tomo to value its medical IP assets for an anticipated Spin-Off.

Key Points: 
  • As previously announced, Endonovo hired Ocean Tomo to value its medical IP assets for an anticipated Spin-Off.
  • Endonovo will retain its non-medical PEMF assets and the future telehealth division.
  • Ocean Tomo is a leading provider of expert opinion and consulting services for IP and intangible assets.
  • The last valuation report issued for Endonovo’s SofPulse® IP and assets, completed in 2018, stated that these assets were worth $75 million.

Endonovo Announces Distribution Agreement with Academy Medical

Retrieved on: 
Monday, March 6, 2023
VHA, SDVOSB, PEMF, Edema, Growth, Veterans Health Administration, Pain, British, Therapy, Quality of life, Health, United States Department of Defense, IDIQ, Agreement, Veteran, Partnership, OTCQB, Department of Defense Medical Examination Review Board, Department of Defence, FDA, Weisberg, Government Affairs Institute, Health insurance, Birth control, Pharmaceutical industry, Defense

Los Angeles, CA, March 06, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced the signing of a Service-Disabled Veteran-Owned Small Business (SDVOSB) Government Reseller Agreement (Agreement or Contract) with Academy Medical, Inc. of West Palm Beach, FL to distribute SofPulse® medical devices to ensure its availability to the Veterans Health Administration (VHA) and Department of Defense (DoD) contracts.

Key Points: 
  • The new Contract allows Academy Medical and Endonovo to team up and bring top-notch medical and surgical supplies, as well as telehealth solutions, to our military and veterans.
  • Additionally, this Agreement allows Academy Medical to provide its expertise in the procurement process of medical and surgical supplies to enhance access to the federal medical marketplace and the distribution of SofPulse®.
  • "Academy Medical is proud to partner with Endonovo’s SofPulse® and bring our expertise in the federal procurement process to this exciting partnership," said John Campbell, Vice President/Government Affairs from Academy Medical.
  • It also has the potential to drive growth and expansion for both Academy Medical and Endonovo as they work together to provide better medical solutions to veterans.

New Details on Endonovo’s Spin-Off of SofPulse, Inc.

Retrieved on: 
Thursday, January 19, 2023
Therapy, Weisberg, Marketing, Patient, Intelligence, Software, OTCQB, 3D printing, Management, Pharmaceutical industry

The new company will be overseen by Ira Weisberg, the current President and Chief Commercial Officer of Endonovo's Medical Division, who will serve as CEO/President.

Key Points: 
  • The new company will be overseen by Ira Weisberg, the current President and Chief Commercial Officer of Endonovo's Medical Division, who will serve as CEO/President.
  • The planned spin-off of SofPulse, Inc. is expected to be completed later in 2023.
  • SofPulse Inc. will feature SofPulse® medical devices designed to provide a viable alternative to opioid pain management for surgical patients.
  • Focusing on drug-free pain management, we should be able to increase revenues in the U.S., international, active/retired military and consumer medical markets.”

Endonovo Announces Advancement of International “Go to Market” Initiative

Retrieved on: 
Monday, December 19, 2022
American Society for Aesthetic Plastic Surgery, Compound annual growth rate, NewCo, Pain, OTCQB, Weisberg, Therapy, Pain management, Growth, Patient, International Society, PEMF, Physician, Field line, Swelling, FDA, Hospital, Edema, Negotiation, Risk management, Dentistry, Pharmaceutical industry

President and Chief Commercial Officer of the Medical Division of Endonovo, Ira Weisberg, will be heading the efforts to expand the benefits of SofPulse® into international markets.

Key Points: 
  • President and Chief Commercial Officer of the Medical Division of Endonovo, Ira Weisberg, will be heading the efforts to expand the benefits of SofPulse® into international markets.
  • “Our international ‘Go to Market’ strategy is to introduce the benefits of SofPulse® into global markets to provide an alternative approach for the management of post-operative pain.
  • Our international partners will aggressively market the benefits of SofPulse® to gain rapid acceptance in these territories,” Weisberg stated.
  • Weisberg’s previous work with medical devices through international partners increased sales for his previous companies netting over $50 million in sales.

Endonovo Announces Plans for Spin-off of Medical IP and Assets

Retrieved on: 
Thursday, December 15, 2022
Weisberg, Swelling, NewCo, Security (finance), Marketing, PEMF, Pain, IPO, Construction, OTCQB, IP, Therapy, Risk factor, Senior, Sustainability Accounting Standards Board, Intellectual property, Corporate development, Pharmaceutical industry, Management, Risk management

Los Angeles, CA, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced plans to affect a spin-off of its medical device assets to a new company (“NewCo”) being formed by its current President and Chief Commercial Officer of its Medical Division, Ira Weisberg.

Key Points: 
  • Weisberg will be responsible for running NewCo independently from Endonovo and will develop commercialization initiatives through sales and marketing channels for NewCo utilizing the SofPulse® medical assets.
  • They will be tasked to develop a valuation of medical Intellectual Property (IP) assets through a fairness opinion report.
  • The last valuation report issued for SofPulse® IP and assets stated that these assets were worth $75 million in 2018.
  • Weisberg has previous successes in growing multiple medical devices and pharmaceutical companies to profitability and increasing valuations of medical assets in excess of $750 million.

Endonovo Launches Telehealth Initiative

Retrieved on: 
Tuesday, December 13, 2022
Weisberg, Physician, Inflammation, Security (finance), FDA, Edema, PEMF, Pain, Construction, OTCQB, Research, Therapy, Risk factor, Patient, Pharmaceutical industry

Los Angeles, CA, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced the launching of a new initiative to utilize its telehealth platform to educate and provide prescription and “over the counter” non-opioid pain reduction options.

Key Points: 
  • Los Angeles, CA, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced the launching of a new initiative to utilize its telehealth platform to educate and provide prescription and “over the counter” non-opioid pain reduction options.
  • The Endonovo Telehealth platform will provide alternative pain management options through its direct-to-consumer sales of prescription and non-prescription uses of their SofPulse® Pulsed Electro Magnetic Frequency (PEMF) medical device proven to reduce opioid use.
  • Weisberg will head company development and implementation of strategic approaches for non-opioid pain management initiatives based on latest advances in telehealth services and related technologies.
  • “Our initiative is targeted to utilize the latest medical market research and planning, development of a robust telehealth platform and identifying and employing a leading telehealth partners that has expertise in HIPAA compliance and a proven ability to promote the initiative effectively to potential users.

Endonovo Names Ira Weisberg President to Guide Global Medical Expansion

Retrieved on: 
Wednesday, November 30, 2022
Marketing, Growth, Wound healing, PEMF, Edema, Pain, Construction, Knowledge, Risk factor, Corporate development, Therapy, Patient, Narcotic, IPO, Inflammation, Adhesive, Senior, Security (finance), CE, Hertz, OTCQB, Weisberg, FDA, Airline, Medical imaging, Pharmaceutical industry, Risk management, Operation

Los Angeles, CA, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) today named Ira Weisberg as President and Chief Commercial Officer of its Medical Division.

Key Points: 
  • Los Angeles, CA, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) today named Ira Weisberg as President and Chief Commercial Officer of its Medical Division.
  • Throughout his career, Weisberg led negotiations and signed licensing deals for strategic acquisitions, distribution and development deals for multiple companies in the medical device and pharmaceutical industry.
  • His expertise is in developing strategies to guide emerging medical companies to advance revenue and enhance company diversity, developmental pipelines and geographic reach particularly in fast-growing emerging medical device and pharmaceutical markets.
  • Weisberg said in accepting the position: "I am thrilled to be joining the Endonovo team at such an exciting time.

Former Waze and Google Executive Named Chief Marketing Officer at E INC

Retrieved on: 
Tuesday, December 21, 2021
TSX, Marketing, INC, Bloomberg, Technology, Publication, Inc. (magazine), Time, The Coca-Cola Company, CEO, CMO, Google, Navigation, Weisberg, GPS, TechCrunch, E, One-to-one, Adweek, WhyHunger, Entrepreneurs Roundtable Accelerator, Retail

TORONTO, Dec. 21, 2021 /PRNewswire/ - E Automotive Inc. d/b/a E INC (TSX: EINC ) (the "Company" or "E INC") today named its first Chief Marketing Officer, Emma Weisberg.

Key Points: 
  • TORONTO, Dec. 21, 2021 /PRNewswire/ - E Automotive Inc. d/b/a E INC (TSX: EINC ) (the "Company" or "E INC") today named its first Chief Marketing Officer, Emma Weisberg.
  • Bringing nearly two decades of experience leading marketing and sales for global brands, Weisberg is joining the company's executive leadership team to bring a forward-thinking approach on marketing strategies, rigorous analytics, and purpose-driven communications in support of the company's strategic plan.
  • "E INC is an innovative technology company transforming the way automotive dealers buy, sell and manage inventory and thus impacting the consumer car shopping experience as well," said Weisberg.
  • "I look forward to bringing my background in the tech sector to help build and accelerate the brand to achieve its full potential."